Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VIAL-IL13xTSLP
- Development stage
- Unknown
- Lead developer
- Vial
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
VIAL-IL13xTSLP is a novel, half-life extended bispecific antibody developed by Vial (Vialis) for the treatment of Type 2 inflammatory diseases, including asthma, atopic dermatitis, chronic obstructive pulmonary disease (COPD), and chronic sinusitis. The drug is engineered to simultaneously bind and neutralize Interleukin-13 (IL-13), a key effector cytokine, and Thymic Stromal Lymphopoietin (TSLP), an upstream alarmin. By targeting both an upstream trigger and a downstream effector of the Type 2 pathway, VIAL-IL13xTSLP aims to provide broader and more potent inhibition of inflammation compared to monospecific antibodies. The program incorporates half-life extension technology intended to enable infrequent dosing at projected quarterly-to-biannual intervals. It is currently in Phase 1 clinical development to evaluate safety, tolerability, and proof-of-mechanism.
- Other names
- Vial IL-13 x TSLP bispecific antibody
02
Targets
IL-13 (Interleukin-13)TSLP (Thymic stromal lymphopoietin)
Beyond the preview
Go deeper on VIAL-IL13xTSLP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VIAL-IL13xTSLP.